Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Breast Neoplasms 37Neoplasms 3Neoplasm Metastasis 3Breast Diseases 3Neoplasms by Site 2Triple Negative Breast Neoplasms 1Skin Diseases 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Ductal, Breast 1Breast Neoplasms, Male 1Breast Neoplasm Female 1Breast Cancer Female 1Advanced Breast Carcinoma 1

Interventions

Carboplatin 85pembrolizumab 78Pemetrexed 68Cisplatin 56Paclitaxel 45osimertinib 41Nivolumab 40durvalumab 37Docetaxel 33atezolizumab 20Gemcitabine 18Radiotherapy 17Radiosurgery 16amivantamab 15Ipilimumab 15130-nm albumin-bound paclitaxel 14Taxes 13Specimen Handling 12Magnetic Resonance Spectroscopy 12Crizotinib 11lazertinib 9Radiation 9Immunoglobulin G 9Drug Therapy 9Disulfides 9Bevacizumab 9tislelizumab 8cemiplimab 8alectinib 8Erlotinib Hydrochloride 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Non-Small-Cell Lung × Anastrozole × Clear all
NCT02779751 2026-01-26

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

Eli Lilly and Company

Phase 1 Active not recruiting
100 enrolled
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡